Regulatory Amgen’s BiTE for lung cancer backed for EU approval PharmaphorumAmgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.RegulatoryOncologyRead full story pharminent March 30, 2026 (Last updated: March 30, 2026) Pharmaphorum Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP. RegulatoryOncologyRead full story Post navigation Previous: Trustworthy AI in clinical oversightNext: The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
